## MRNA: Moderna, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 2.5% below STRENGTH zone (4.0-10.0%); PEG 2.44 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-3.5% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($27.84)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. Moderna to Host Investor Event – Analyst Day**
- Source: columbiadailyherald.com | 20260101T140812 | Neutral | Relevance: 100%
- Moderna, Inc. (Nasdaq: MRNA) announced it will host an Investor Event – Analyst Day on Thursday, November 20, 2025, at 9:00 a.m. ET. The event will feature presentations from management discussing the company's development and commercial strategy and key business considerations. A live webcast and subsequent replay will be available through Moderna's website for investors.

**2. CEPI to Fund Pivotal Phase 3 Trial for Moderna's mRNA Pandemic Influenza Vaccine Candidate**
- Source: Milford Daily News | 20260101T060831 | Bullish | Relevance: 100%
- The Coalition for Epidemic Preparedness Innovations (CEPI) will invest up to $54.3 million to support Moderna's pivotal Phase 3 clinical trial for its mRNA-based H5 pandemic influenza vaccine candidate, mRNA-1018. This funding aims to accelerate the vaccine towards licensure, enhancing global preparedness against pandemic threats and potentially revolutionizing response times. Moderna has committed to allocating 20% of its H5 pandemic vaccine manufacturing capacity for timely and affordable supply to low- and middle-income countries if the vaccine is licensed.

**3. Moderna to Host Investor Event – Analyst Day**
- Source: Galesburg Register Mail | 20260101T000818 | Neutral | Relevance: 100%
- Moderna (Nasdaq: MRNA) announced it will host its Investor Event – Analyst Day on Thursday, November 20, 2025, at 9:00 a.m. ET. The event will feature management discussions on Moderna's development, commercial strategy, and key business considerations, and will be webcast live. Moderna, a leader in mRNA medicine, aims to transform disease treatment and prevention through its innovative platform.

**4. Moderna (MRNA) Falls More Steeply Than Broader Market: What Investors Need to Know**
- Source: www.sharewise.com | 20251231T034640 | Somewhat-Bearish | Relevance: 100%
- Moderna (MRNA) closed down 2.38% in a recent trading session, underperforming the broader S&P 500, Dow, and Nasdaq markets. Despite this daily dip, the stock gained 28.93% over the past month, significantly outpacing the Medical sector. Analysts predict an EPS of -$2.79 and revenue of $683.27 million for its upcoming earnings release.

**5. Moderna to Host Investor Event – Analyst Day**
- Source: Ventura County Star | 20251231T020835 | Neutral | Relevance: 100%
- Moderna, Inc. announced it will host an Investor Event – Analyst Day on Thursday, November 20, 2025, at 9:00 a.m. ET. The event will feature presentations from management detailing Moderna's development and commercial strategy and key business considerations. A live webcast and subsequent replay will be available on Moderna's investor website.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-12 | Morgan Stanley | $28 | $30 | -7% |
| 2025-12-12 | Jefferies | $30 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-12 | Morgan Stanley | main | Equal-Weight |
| 2025-12-12 | Jefferies | init | Hold |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 3 ($0.26M) |
| Sells | 10 ($0.60M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 42.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 10.5% (-1.2%)
- Blackrock Inc.: 7.6% (+3.2%)
- BAILLIE GIFFORD & CO: 5.6% (-1.1%)
- State Street Corpora: 4.4% (-0.9%)
- FMR, LLC: 3.1% (-37.4%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-3.5% 5d) with bearish MACD, trend may be turning.
2. High short interest (21.7%, 7.0 days to cover): squeeze risk or crowded bearish bet.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 2.44 elevated, pricing in significant growth expectations. Balance sheet: strong liquidity (3.9x), low leverage (D/E 0.30). Analyst sentiment negative (1 target cuts vs 0 raises). Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $12.1B |
| Beta | 1.11 |
| 52W Range | $22.28 - $48.92 |
| Short Interest | 21.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.44 |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_20 deteriorating from 6.0% to 2.5% (-3.5% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 1.5pp (needs >4.0% for momentum thesis). MRS_5 at 1.5% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 56. OFD pattern: +MUN (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 2.48% (CS: 75) | Neutral |
| RSI_14 | 55.9 | Neutral |
| MACD Histogram | -0.25 | Bearish |
| vs SMA20 | 1.019x | Above |
| vs SMA50 | 1.135x | Above |
| vs SMA200 | 1.127x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $30.86
- **Stop Loss:** $27.84 (9.8% risk)
- **Target:** $33.88 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 476
- **Position Value:** $14,689.36
- **Portfolio %:** 14.69%
- **Risk Dollars:** $1,440.00
- **Risk Per Trade:** 1.44%
- **Modifiers:** L1 120% | L2 120% | Combined 1.44x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.20x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with stable risk appetite as 2026 trading begins. VIX at 14.51 (4th percentile) signals complacency while positive yield curve (+65bps) and moderate breadth (53.1%) support continuation. Focus on upcoming jobs data (Jan 9) and earnings season kickoff mid-January for directional catalysts.*

### Earnings

**Next:** 2026-02-12 (Est: $-2.73)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-2.18 | $-0.51 | +76.6% |
| 2025Q2 | $-2.97 | $-2.13 | +28.3% |
| 2025Q1 | $-3.18 | $-2.52 | +20.7% |
| 2024Q4 | $-2.76 | $-2.91 | -5.4% |

---
*RULE-based L3 | 2026-01-06 17:52 | MRS_20*